The use of digital endpoints provides substantial financial value to drug developers, with significant positive changes in expected net present value (eNPV) and high returns on investment (ROI). These benefits are primarily driven by shorter clinical trial durations and smaller participant enrollment sizes. The financial gains are considerably larger in Phase III trials compared to Phase II, which is attributed to the higher probability of a drug successfully reaching the market from the later stage. While the upfront investment for implementation is significant, the financial returns justify the cost across the therapeutic areas analyzed.
Recommendations
Sponsors should develop cross-portfolio strategies for digital measures to optimize and scale the value captured across their development programs. Engaging in precompetitive collaborations is encouraged to share the risks and costs of development, harmonize new measures across the industry, and increase overall returns. Organizations should continue to invest in these capabilities, as their widespread adoption can transform the drug development process and, ultimately, deliver safe and effective treatments to patients sooner.
Regulatory Considerations
While a deep analysis of the regulatory environment is outside the paper’s scope, it acknowledges that the evolving regulatory landscape is critical for fostering innovation in clinical development. To support broader adoption and understanding, the authors suggest that clinical trial registries should expand their data collection to include specific details on the use and outcomes of digital endpoint strategies. This would improve transparency and help build the evidence base for the impact of these novel measures on clinical research.